Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2020 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
February 06, 2020 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
January 13, 2020 06:00 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma

Increasing BCMA Surface Expression with Gamma Secretase Inhibitor Nirogacestat May Enable Deep and Durable Responses to ALLO-715, an Investigational Anti-BCMA Allogeneic CAR T Therapy SOUTH SAN...
January 02, 2020 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric...
November 11, 2019 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
November 06, 2019 09:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric...
November 05, 2019 07:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Third Quarter 2019 Financial Results

Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM)Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) with...
November 05, 2019 06:28 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma Notch to Receive Upfront Payment, Research Funding and an Equity...
October 29, 2019 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
September 19, 2019 08:00 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies

Collaboration Will Evaluate Charge-altering Releasable Transporter System for mRNA Delivery to T CellsResearch Will Be Led by Stanford Researchers Robert Waymouth, Ph.D., Paul Wender, Ph.D. and Ronald...